These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 32349585

  • 1. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H, Feng S, Lu Y, Jiang L, Yang T, Wang Z.
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [Abstract] [Full Text] [Related]

  • 2. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 3. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB.
    Circulation; 2016 Jul 05; 134(1):61-72. PubMed ID: 27358438
    [Abstract] [Full Text] [Related]

  • 4. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 05; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN.
    Atherosclerosis; 2018 Oct 05; 277():477-482. PubMed ID: 30270088
    [Abstract] [Full Text] [Related]

  • 6. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep 05; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 7. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M, Fukumoto Y.
    J Atheroscler Thromb; 2021 Apr 01; 28(4):329-337. PubMed ID: 32624555
    [Abstract] [Full Text] [Related]

  • 8. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY.
    J Am Heart Assoc; 2016 Apr 29; 5(5):. PubMed ID: 27130349
    [Abstract] [Full Text] [Related]

  • 9. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD, Lee SE, Yang J, Lee HC, Shin D, Lee H, Lee J, Jin S, Kim S, Lee SJ, You J, Park HW, Nam KY, Lee SH, Park SW, Kim JS, Kim SY, Kwon YW, Kwak SH, Yang HM, Kim HS.
    Eur Heart J; 2020 Jan 07; 41(2):239-252. PubMed ID: 31419281
    [Abstract] [Full Text] [Related]

  • 10. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S, Vaziri ND.
    Nephrol Dial Transplant; 2014 Mar 07; 29(3):538-43. PubMed ID: 24166456
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 07; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 12. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S, Rodríguez-Pérez C, Ramprasath VR, Segura-Carretero A, Jones PJ.
    Vascul Pharmacol; 2016 Dec 07; 87():60-65. PubMed ID: 27374222
    [Abstract] [Full Text] [Related]

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
    Feder S, Wiest R, Weiss TS, Aslanidis C, Schacherer D, Krautbauer S, Liebisch G, Buechler C.
    Lipids Health Dis; 2021 Jan 18; 20(1):6. PubMed ID: 33461570
    [Abstract] [Full Text] [Related]

  • 14. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
    Bianconi V, Schiaroli E, Pirro M, Cardaci S, Busti C, Mannarino MR, Baldelli F, Francisci D.
    HIV Med; 2020 Sep 18; 21(8):512-522. PubMed ID: 32496664
    [Abstract] [Full Text] [Related]

  • 15. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS.
    JAMA Cardiol; 2017 May 01; 2(5):556-560. PubMed ID: 28122070
    [Abstract] [Full Text] [Related]

  • 16. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X.
    Curr Drug Targets; 2019 May 01; 20(10):1029-1040. PubMed ID: 30767742
    [Abstract] [Full Text] [Related]

  • 17. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C.
    Li S, Zhao X, Zhang Y, Zhu CG, Guo YL, Wu NQ, Xu RX, Qing P, Gao Y, Sun J, Liu G, Dong Q, Li JJ.
    Oncotarget; 2017 Feb 14; 8(7):12333-12341. PubMed ID: 27713142
    [Abstract] [Full Text] [Related]

  • 18. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
    Du Q, Yu XJ, Li HJ, Guan SQ, Zhang ZY, Mei YF.
    Zhonghua Nei Ke Za Zhi; 2017 Sep 01; 56(9):655-659. PubMed ID: 28870033
    [Abstract] [Full Text] [Related]

  • 19. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS, Awan Z, Bouchard A, Champagne J, Tessier S, Faubert D, Chabot K, Garneau PY, Rabasa-Lhoret R, Seidah NG, Ridker PM, Genest J, Coulombe B.
    J Clin Lipidol; 2018 Sep 01; 12(4):1027-1038. PubMed ID: 29699916
    [Abstract] [Full Text] [Related]

  • 20. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI, Astrakova KS, Shakhtshneider EV, Stakhneva EM, Gafarov VV, Bogatyrev SN, Voevoda MI.
    Kardiologiia; 2017 Apr 01; 57(4):72-76. PubMed ID: 28762908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.